Proleukin aldesleukin: Phase III; marketed to treat metastatic renal carcinoma and metastatic melanoma

CHIR discontinued its open-label Phase III SILCAAT trial, which was comparing aldesleukin plus antiretroviral therapy to antiretroviral therapy alone in 1,957 HIV patients with low CD4 counts. The pri...